India, May 14 -- Curanex Pharmaceuticals Inc. (CURX), a pharmaceutical development company, on Thursday announced first quarter results and highlighted progress of its lead drug candidate Phyto-N, which is being advanced towards a planned FDA submission for ulcerative colitis.
Q1 2026:
Curanex reported cash and cash equivalents on March 31, 2026, amounting to $4 million. The company estimated that the available capital will be sufficient to support key upcoming development activities for its lead drug candidate Phyto-N.
Pipeline Highlights:
Phyto-N is being evaluated as a potential treatment of ulcerative colitis in studies to determine toxicology and pharmacokinetics of the drug.
A preclinical toxicology, dose-finding trial was comple...